Trials: Meningitis, Meningococcal

Phase 2 N=378 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

HIV Infections · Meningitis

Primary: Number of Immunogenic Responders, With Response Defined as a 4-fold or Greater Increase in Serum Bactericidal Antibody Titers From Study Entry to Week 28 After 2 Doses…

National Institute of Allergy and Infectious… Results May 2014 4.2% serious AE View details

Phase 2 N=500 Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Infections, Meningococcal

Primary: Vaccine Response to Meningococcal Antigens for Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 82.7; 69.7; 94.4; 90.3 Percentage of subjects

GlaxoSmithKline Results Jun 2018 0.2% serious AE View details

Phase 1 N=34 Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

Primary: Safety: Severity Summary of Solicited and Unsolicited Adverse Events — 67; 92; 70; 3 AEs

U.S. Army Medical Research and Development Command Results Oct 2018 0.0% serious AE View details

Phase 2 N=1,715 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 1.0% serious AE View details

Phase 2 N=376 Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Meningitis, Meningococcal

Primary: Severe Solicited Adverse Event — 0; 0; 0; 0 participants

Serum Institute of India Pvt. Ltd. Results Sep 2021 0.4% serious AE View details

Phase 3 N=360 Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Primary: Percentage of Participants With Vaccine Seroresponse For Meningococcal Serogroup A, C, Y And W Following Vaccination With MenACYW Conjugate and Menactra® Vaccine…

Sanofi Results Oct 2021 0.0% serious AE View details

Phase 2 N=601 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Prevention of Meningococcal Disease

Primary: Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine — 6; 0; 93; 81 percentages of…

Novartis Vaccines Results Jun 2014 12.2% serious AE View details

Phase 2 N=301 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Antibody Titers ≥1:4 and ≥1:8 Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 0.0% serious AE View details

Phase 2 N=1,713 A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Meningococcal Vaccine

Primary: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation: Group 1 and…

Pfizer Results Jun 2015 2.5% serious AE View details

Phase 3 N=290 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

Healthy Volunteers (Meningococcal Infection)

Primary: Percentage of Participants With Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal…

Sanofi Pasteur, a Sanofi Company Results Mar 2025 2.1% serious AE View details

Phase 3 N=1,118 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningococcal Meningitis · Measles · Mumps

Primary: Percentage of Participants With Antibody Titers ≥ 8 After Visit 2 Menactra® Vaccination as Measured by Serum Bactericidal Assay Using Human Complement (SBA-HC) — 96; 93…

Sanofi Pasteur, a Sanofi Company Results Jun 2011 3.8% serious AE View details

Phase 3 N=463 Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Meningococcal Immunisation · Healthy Volunteers

Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y Measured by hSBA Following Vaccination With MenACYW Conjugate…

Sanofi Pasteur, a Sanofi Company Results Jun 2023 0.2% serious AE View details

Phase 2 N=524 Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Prevention of Meningococcal Disease

Primary: Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without…

Novartis Vaccines Results Nov 2013 2.5% serious AE View details

Phase 2 N=188 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Number of Participants Reporting Solicited Injection-Site and Systemic Reaction Following Vaccination With Either MenACYW Conjugate Vaccine or NIMENRIX® — 28; 31; 0; 1…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 0.5% serious AE View details

Phase 2 N=54 Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Meningococcal Disease

Primary: Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination. — 2.5; 2.3; 1.8; 33 titer

Novartis Vaccines Results Jul 2011 0.0% serious AE View details

Phase 3 N=300 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Meningococcal Infection · Meningitis

Primary: Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination — 17; 27; 23; 95 Participants

Sanofi Results Feb 2012 0.0% serious AE View details

Phase 3 N=1,325 Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Meningitis

Primary: Number of Participants With Seroprotection for Meningitis Serogroups A, C, W and Y — 373; 191; 366; 180 Participants

Emory University Results May 2024 0.4% serious AE View details

Phase 3 N=1,183 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Meningitis, Meningococcal

Primary: Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 1.2% serious AE View details

Phase 3 N=450 Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Neisseria Meningitidis · Meningococcal Infections

Primary: Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination…

Sanofi Pasteur, a Sanofi Company Results Mar 2011 0.2% serious AE View details

Phase 2 N=103 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Meningitis · Meningococcemia

Primary: Geometric Mean of Antibody Titers (GMTs) as Measured by Serum Bactericidal Assay (SBA) at Baseline (Day 0) and Day 28 Post-vaccination. — 136.33; 99.66; 11404.16; 199.31…

Sanofi Pasteur, a Sanofi Company Results Apr 2009 1.0% serious AE View details

Phase 3 N=1,500 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Meningococcal Disease

Primary: Percentage of Subjects With hSBA Seroresponse Against Serogroups A, C, W and Y One Month After Vaccination With MenACWY-CRM or MenACWY-PS — 93; 55; 82; 52 Percentage of…

Novartis Vaccines Results Nov 2013 0.7% serious AE View details

Phase 3 N=918 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W in Toddlers Who Either Were…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 0.8% serious AE View details

Phase 3 N=810 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine…

Sanofi Pasteur, a Sanofi Company Results Jun 2020 1.1% serious AE View details

Phase 2 N=400 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION

Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…

Pfizer Results Mar 2018 1.5% serious AE View details

Phase 3 N=950 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

Primary: Infants Groups 1 and 2: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at 30 Days Post Second…

Sanofi Pasteur, a Sanofi Company Results Jun 2024 2.5% serious AE View details

Phase 3 N=13 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Prevention of the Meningococcal Disease

Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule — 1.18; 53; 2.27; 143 Titers

Novartis Vaccines Results Oct 2014 0.0% serious AE View details

Phase 3 N=570 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

Primary: Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59…

Sanofi Pasteur, a Sanofi Company Results Aug 2021 1.1% serious AE View details

Phase 3 N=788 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Healthy Volunteers (Meningococcal Infection)

Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination…

Sanofi Pasteur, a Sanofi Company Results Nov 2023 7.5% serious AE View details

Phase 3 N=906 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune®…

Sanofi Pasteur, a Sanofi Company Results Feb 2020 3.3% serious AE View details

Phase 3 N=3,293 A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Healthy

Primary: Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite…

Pfizer Results Feb 2016 1.3% serious AE View details

Clinical Trial Search

Phase 2 N=378 Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Phase 2 N=500 Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Phase 1 N=34 Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Phase 2 N=1,715 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Phase 2 N=376 Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Phase 3 N=360 Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Phase 2 N=601 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Phase 2 N=301 Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Phase 2 N=1,713 A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Phase 3 N=290 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon

Phase 3 N=1,118 A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Phase 3 N=463 Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Phase 2 N=524 Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Phase 2 N=188 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Phase 2 N=54 Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Phase 3 N=300 A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Phase 3 N=1,325 Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

Phase 3 N=1,183 Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Phase 3 N=450 Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

Phase 2 N=103 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Phase 3 N=1,500 Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Phase 3 N=918 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Phase 3 N=810 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Phase 2 N=400 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Phase 3 N=950 Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Phase 3 N=13 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Phase 3 N=788 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Phase 3 N=906 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Phase 3 N=3,293 A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.